SEC Filing Summary: Cerulean Pharma Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by Cerulean Pharma Inc. on August 4, 2016. The filing serves to announce operational highlights for the three and six months ended June 30, 2016, and outlines anticipated corporate and clinical milestones for the remainder of 2016. The detailed financial and operational data is contained within a press release attached as Exhibit 99.1.
Key Financial Metrics
The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1), which is incorporated by reference but not included in the provided text.
Material Changes
The filing indicates the announcement of operational highlights for the periods ended June 30, 2016. Specific quantitative comparisons to prior periods are not present in the filing text.
Guidance, Outlook, and Risks
Management has provided anticipated corporate and clinical milestones for the remainder of 2016. The filing includes a standard disclaimer stating that the information provided under Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section, except as expressly set forth by specific reference.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific revenue, cash burn, and liquidity figures for the six months ended June 30, 2016.
- Verify the specific clinical milestones and timelines announced for the remainder of 2016.
- Confirm the company's cash runway and funding status as detailed in the referenced press release.
- Note the legal disclaimer regarding the "furnished" status of the operational data versus "filed" data.